ESMO Asia 2023 | Ideal treatment duration of tyrosine kinase inhibitors in EGFR-mutant NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East, Chiba, Japan, discusses the ideal length of trials assessing the use of tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). The ADAURA trial (NCT02511106) had a follow up of 3 years due to a plateau of events in the control arm after this length of time. Dr Tsuboi addresses 2 year follow ups in other trials and states that if a biomarker could be used (e.g. ctDNA) to show patients they had little risk of disease after 2 years, some patients could reduce the length of therapy. Additionally, in rare mutations, there is an increase in disease reoccurrence after 3 years, therefore, trials are in development with 5 year follow ups for these patients. Again, this is unlikely to be necessary for all patients, so a biomarker to assess the therapeutic need of individual patients would be useful. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.